Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-11 of 11 for your search:
Cancer Type/Condition:
Brain tumor, child: General & other
Stage/Subtype:
childhood ependymoblastoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
2.
Phase I/II Study of MET Tyrosine Kinase Inhibitor PF-02341066 in Children With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 21
Sponsor:
NCI
Protocol IDs:
COG-ADVL0912
, ADVL0912, NCT00939770
3.
Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 30
Sponsor:
Other
Protocol IDs:
OHSU-5056
, OHSU SOL-08131-L, NCT00983398
4.
A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
15 and over
Sponsor:
Other
Protocol IDs:
12555
, NCT00589706
5.
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
CERN08-01
, NCT00883688
6.
A Trial of RAD001 and Avastin in Children With Recurrent Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
RADBEV
, NCT00756340
7.
Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 months to 23 years
Sponsor:
Other
Protocol IDs:
ACH-CNS-001
, NCT00876993
8.
Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Under 21
Sponsor:
Other
Protocol IDs:
08-1017
, NCT00935545
9.
Phase I Study of ABT-888 and Temozolomide in Pediatric Patients With Recurrent or Refractory CNS Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
21 and under
Sponsor:
NCI
Protocol IDs:
PBTC-027
, PBTC-027, NCT00946335
10.
Magnetic Resonance Temperature Imaging & Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2007-0610
, NCT00720837
11.
Pilot Study of HLA-A2-Restricted Synthetic Glioma Antigen Peptide Vaccine and Poly ICLC Vaccine in Young Patients With Newly Diagnosed Malignant or Intrinsic Brain Stem Glioma, Incompletely Resected Non-Brainstem High-Grade Glioma, or Recurrent Unresectable Low-Grade Glioma
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
3 to 20
Sponsor:
Other
Protocol IDs:
CHP-PRO08030085
, PRO08030085, NCT00862199
Select All on Page
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
